Background: To evaluate the tolerance and efficacy of the combination of paclitaxel and gemcitabine as salvage treatment in patients with advanced non-small-cell lung cancer (NSCLC).
Introduction

Patients and methods
Paclitaxel, which promotes tubulin polymerization and inhibits microtubule assembly [1] , has shown interesting activity against NSCLC, with responses ranging from 21% to 24% and a 40% one-year survival [2] [3] [4] . Moreover, a 23% response rate was reported with paclitaxel in 30 previously treated patients [5] . Gemcitabine is also active in both chemo-nai've [6] [7] [8] and previously-treated [9] patients with advanced NSCLC, with responses ranging from 20% to 25%. This drug, after its intracellular phosphorylation and activation, inhibits DNA synthesis and repair [10] .
Based on the demonstrated single-agent activity of paclitaxel and gemcitabine in previously-treated patients with NSCLC and their different mechanisms of action, the Greek Cooperative Group for Lung Cancer conducted a phase II trial to evaluate the efficacy and tolerance of their combination as salvage treatment in patients with advanced NSCLC.
Patient selection
Patients (aged 18-75 years), with comfirmed and bidimensionally measurable stage 1MB or IV NSCLC were enrolled. Other eligibility criteria were: progression or relapse after first-line treatment; an at least four-week interval since the prior chemotherapy; a World Health Organization (WHO) PS 0-2; a life expectancy of at least three months; adequate hematologic parameters (absolute granulocyte count (AGC)> 1.500/dl, platelet count> 130.000/dl); adequate renal (serum creatinine <1.5 mg/dl) and hepatic (serum bilirubin <2.0 mg/dl) function tests and normal cardiac function; brain metastases were allowed provided that they were irradiated, with clinical and radiologic improvement. Exclusion criteria were: severe infection, malnutrition or a second malignancy (excluding nonmelanomatous skin cancer and in situ cervical carcinoma). All patients gave their written informed consent.
Staging and treatment evaluation
Pretreatment evaluation included a complete medical history and physical examination; a complete blood cell count (CBC) and biochemical profile, an electrocardiogram, chest X-rays, computed tomography (CT) scans of the chest, abdomen and brain, and a whole bone The doses of both drugs were reduced by 25% in instances of febrile neutropenia or grade 4 thrombocytopenia continuing longer than five days. In the absence of fever, all drugs were reduced by 15% in instances of grade 4 neutropenia or/and grade 2-3 thrombocytopenia. Treatment was delayed by one week and the paclitaxel dose was reduced by 25% in patients with grade 3 neurotoxicity. Standard WHO criteria [11] were used to evaluate the response to treatment and toxicities. All responses were validated by an external board of radiologists.
Statistical methods
The duration of response was calculated from the day of the treatment initiation to disease progression; overall survival was measured from study entry to death Actuarial probability of survival and time to tumor progression (TTP) were estimated by the method of Kaplan and Meier. Proportions were compared by the Pearson's chi-square test; the 95% binomial exact confidence intervals (CI) were also calculated.
Results
Response to treatment
Forty-nine patients were enrolled (from January 1996 to June 1997) and their characteristics are shown in Table 1 . One CR (2%) and eight (16%) PRs were observed (ORR: 18%, 95% CI: 4%-24%); 14 (29%) patients had SD and 26 (53%o) PD. Response rate was independent of histology, stage of the disease or PS. The first-line treatment of responders was: CDDP-based (n = 4); docetaxel-CDDP (n -4) and docetaxel-vinorelbine (n = 1). The median interval between the first-and second-line chemotherapies was five weeks (range 1-19). Six (35%) responses were documented in 17 patients responding to first-line treatment and three (9%) in 32 patients who had SD/PD (P < 0.05).
scan. During treatment, CBC was performed weekly or daily (in instances of febrile neutropenia, grade 3-4 neutropenia or grade 4 thrombocytopenia until hematologic recovery). A detailed history was taken, a physical examination including neurologic evaluation was completed and biochemical tests, electrocardiogram and chest X-rays were performed before each cycle to document disease symptoms and treatment toxicity. Lesions assessable by physical examination or chest X-rays were measured after each cycle; otherwise, response to treatment was evaluated after three cycles. Patients with disease progression at any time were withdrawn from the study.
Treatment
Gemcitabine (Gemzar; Elli Lilly, Indianapolis, IN, USA) was administrated intravenously at the dose of 900 mg/m 2 , over 30 minutes on days 1 and 8. Paclitaxel (Taxol; Bristol Myers Squibb, Princeton, NJ, USA) was given at the dose of 175 mg/m 2 on day 8 as a three-hour intravenous infusion; standard premedication with diphenydramine and corticosteroids was given to all patients. Recombinant human Granulocyte Colony-Stimulating Factor (rhG-CSF; Granocyte. Rhone Poulenc Rorer, Collegeville, USA), was given prophylactically (150 ug/m 2 subcutaneously; days 9-15) if the AGC nadir was not reached or until the AGC was at least 1.200/dl on two consecutive counts after the nadir. Treatment was administered on an outpatient basis and repeated every three weeks until disease progression.
Compliance with treatment
Two hundred twelve chemotherapy cycles were administered (median three cycles /patient, range 1-11). Twentythree cycles (11%) were delayed for five to 10 days (median six days) because of toxicity (five cycles), nonneutropenic infections (two cycles) or other reasons unrelated to treatment (16 cycles). All patients could receive the day 8 gemcitabine dose. Four patients refused to continue treatment after the first cycle, while in seven patients treatment was stopped because of toxicity. The median dose intensity was 57.5 mg/m 2 /week (range 32-58) for paclitaxel and 594 mg/m 2 /week (range 296-631) for gemcitabine.
Hematologic and non-hematologic toxicity
The toxic effects of the regimen were mild, as shown in Table 2 . Severe neutropenia and thrombocytopenia occurred in six (12%) and one (2%) of the patients, respectively. Neutropenic fever was observed only once, and there were no treatment-related deaths. One patient (14) 3 (7) 1 (2) 12(24) 23 (47) 1 (2) 2 (4) 2 (4) 5 (10) 1 (2) 
with grade 4 diarrhea required hospitalization. Grades 2 and 3 peripheral sensory neurotoxicity were reported in 12 (24%) and four (8%) patients, respectively, but seven of them already had grade 1 or 2 neurotoxicity at the time of enrollment. Twenty-five (51%) patients reported grade 2-3 asthenia with a median duration of 12 days (range 4-25); two of these patients refused further treatment. Other toxicities were mild (Table 2) . Non-neutropenic infections occurred in nine patients (including one case of Pnemonocystis carinii pneumonia); all patients were successfully treated.
Discussion
This report indicates that the paclitaxel-gemcitabine regimen is safe and relatively active in patients with advanced NSCLC who failed first-line chemotherapy with CDDP. Patients who respond to front-line chemotherapy may represent a favorable subgroup of patients with chemosensitive tumors, since 35% of them responded to the paclitaxel-gemcitabine regimen. Moreover, it seems that there is not a complete cross-resistance between the paclitaxel-gemcitabine combination and the docetaxel or/and CDDP, since three major responses were achieved in 32 patients who failed to respond to first-line chemotherapy.
The 11-month patient median survival was an unexpected and interesting observation, since all of the patients had poor prognoses. This observation could be explained by the enrollment of 16 patients who had SD while receiving first-line chemotherapy and thus, less aggressive tumors; moreover, 80% of the patients had a PS 0-1. Therefore, it is possible that patient selection accounts for this favorable survival; only a randomized trial could clarify whether the paclitaxel-gemcitabine combination can confer a survival benefit to these patients.
The hematologic toxicity of the regimen was very mild, with no episodes of neutropenic fever. This could be attributed to either the prophylactic use of G-CSF or/and the schedule of drug administration. However, the G-CSF use makes the regimen expensive, and a future study should evaluate the prevention of febrile neutropenic episodes from the viewpoint of cost-effectiveness. The administration of paclitaxel on day 8 was based on the nadir of paclitaxel-induced neutropenia occurring five to eight days post-treatment [2] . In addition, Poole et al. [12] reported a phase I study where gemcitabine (1000 mg/m 2 on days 1 and 8) could be safely combined with paclitaxel (175 mg/m 2 ) given only on day 8.
Non-hematologic toxicity was mild with grade 2-3 asthenia in 51% of patients, leading to treatment discontinuation in two of them. Moreover, grade 2-3 sensory neurotoxicity occurred in 32% of patients, but one-half of them had already presented grade 1-2 neurotoxicity at the time of enrollment as a consequence of the prior chemotherapy; this observation suggests that this adverse event is dose-dependent and cumulative.
In conclusion, the paclitaxel-gemcitabine combination is a safe, well-tolerated and relatively active salvage regimen in patients with advanced NSCLC; future studies have to further evaluate this regimen, especially in patients who relapse after an initial response to frontline chemotherapy.
